A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine.

Halofantrine hydrochloride (Hf.HCl) is a highly lipophilic phenanthrenemethanol antimalarial. The poor and erratic absorption of Hf after oral administration has been implicated in some treatment failures. Food increases the oral bioavailability of Hf in humans approximately 3-5-fold, although neither the absolute bioavailability nor the basis for the food effect has been fully defined. In this study, the mean (+/-SD, n = 3) absolute oral bioavailability of 250 mg Hf.HCl tablets in beagles was 8.6 +/- 5.3% in the fasted state, which increased approximately 12-fold when administered postprandially. These data indicate that Hf.HCl is efficiently absorbed from the postprandial intestinal environment. The solubility and intrinsic dissolution rate of Hf.HCl were investigated as a function of bile salt concentration (sodium taurocholate, NaTC, 0-30 mM) and micellar composition (4:1 NaTC:lecithin). At premicellar (fasted) concentrations of NaTC (< 5 mM), the solubility and intrinsic dissolution rate were very low (< 15 micrograms/mL; < 0.01 microgram s-1 cm-2). At NaTC concentrations typical of the postprandial state, the solubility and dissolution rate improved dramatically. For example, solubility in 30 mM NaTC increased approximately 1000-fold relative to buffer control, with even greater enhancement (3000-fold) associated with mixed micellar systems. These data suggest that the improved absorption of Hf.HCl in the fed state is most likely due to the increased solubilization and dissolution of the drug in the presence of bile salt mixed micelles.

[1]  A. Breckenridge,et al.  Pharmacokinetics of halofantrine in man: effects of food and dose size. , 1989, British journal of clinical pharmacology.

[2]  M A Mintun,et al.  Dissolution kinetics of carboxylic acids I: effect of pH under unbuffered conditions. , 1981, Journal of pharmaceutical sciences.

[3]  H. Webster,et al.  Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria , 1993, The Lancet.

[4]  H. Webster,et al.  Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand. , 1988, Bulletin of the World Health Organization.

[5]  S. Ward,et al.  Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. , 1991, British journal of clinical pharmacology.

[6]  M. Mintun,et al.  Dissolution kinetics of phenylbutazone. , 1981, Journal of pharmaceutical sciences.

[7]  G. Shanks,et al.  Efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. , 1994, The American journal of tropical medicine and hygiene.

[8]  D. Kyle,et al.  Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. , 1993, British journal of clinical pharmacology.

[9]  H. Pohle,et al.  The efficacy of halofantrine in the treatment of acute malaria in nonimmune travelers. , 1992, The American journal of tropical medicine and hygiene.

[10]  D. Crommelin,et al.  Dissolution rate of griseofulvin in bile salt solutions. , 1991, Journal of pharmaceutical sciences.

[11]  P. Stilbs Fourier transform NMR pulsed-gradient spin—echo (FT-PGSE) self-diffusion measurements of solubilization equilibria in SDS solutions , 1982 .

[12]  D. Crommelin,et al.  Dissolution kinetics of griseofulvin in mixed micellar solutions. , 1994, Journal of pharmaceutical sciences.

[13]  C. Porter,et al.  A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. , 1995, Journal of pharmaceutical and biomedical analysis.

[14]  C. Porter,et al.  Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. , 1996, Journal of pharmaceutical sciences.

[15]  T. Kararli Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.

[16]  S. Looareesuwan,et al.  Clinical trials with halofantrine in acute uncomplicated falciparum malaria in Thailand. , 1993, The Southeast Asian journal of tropical medicine and public health.

[17]  A. J. Repta,et al.  Solubilization and stabilization of an investigational antineoplastic drug (NSC no. 278214) in an intravenous formulation using an emulsion vehicle , 1983 .

[18]  J. Meyer,et al.  The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum. , 1995, British journal of clinical pharmacology.

[19]  D. Kariuki,et al.  EFFICACY OF MULTIPLE-DOSE HALOFANTRINE IN TREATMENT OF CHLOROQUINE-RESISTANT FALCIPARUM MALARIA IN CHILDREN IN KENYA , 1988, The Lancet.